Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Issues Earnings Results

Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTXGet Rating) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03), MarketWatch Earnings reports.

Brooklyn ImmunoTherapeutics stock traded down $0.06 during mid-day trading on Friday, reaching $1.64. 293,627 shares of the stock traded hands, compared to its average volume of 401,772. Brooklyn ImmunoTherapeutics has a 12-month low of $1.60 and a 12-month high of $80.67.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Brooklyn ImmunoTherapeutics by 20.3% during the fourth quarter. BlackRock Inc. now owns 2,147,749 shares of the biotechnology company’s stock valued at $8,956,000 after purchasing an additional 361,682 shares during the period. Wells Fargo & Company MN grew its holdings in Brooklyn ImmunoTherapeutics by 103.2% during the fourth quarter. Wells Fargo & Company MN now owns 57,104 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 28,997 shares during the period. Marshall Wace LLP bought a new position in shares of Brooklyn ImmunoTherapeutics in the fourth quarter worth about $138,000. Cubist Systematic Strategies LLC bought a new position in shares of Brooklyn ImmunoTherapeutics in the fourth quarter worth about $194,000. Finally, State Street Corp boosted its stake in shares of Brooklyn ImmunoTherapeutics by 1.9% in the fourth quarter. State Street Corp now owns 509,258 shares of the biotechnology company’s stock worth $2,124,000 after acquiring an additional 9,398 shares during the period.

Separately, Cantor Fitzgerald initiated coverage on Brooklyn ImmunoTherapeutics in a research note on Wednesday, December 29th. They set an “overweight” rating and a $9.00 price objective for the company.

Brooklyn ImmunoTherapeutics Company Profile (Get Rating)

Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.

See Also

Earnings History for Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX)

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.